Jinhe Biotechnology Operating Margin vs. Price To Book

002688 Stock   4.52  0.04  0.89%   
Based on the key profitability measurements obtained from Jinhe Biotechnology's financial statements, Jinhe Biotechnology Co may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Jinhe Biotechnology's ability to earn profits and add value for shareholders.
For Jinhe Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Jinhe Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Jinhe Biotechnology Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Jinhe Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Jinhe Biotechnology Co over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Jinhe Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Jinhe Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jinhe Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Jinhe Biotechnology Price To Book vs. Operating Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Jinhe Biotechnology's current stock value. Our valuation model uses many indicators to compare Jinhe Biotechnology value to that of its competitors to determine the firm's financial worth.
Jinhe Biotechnology Co is number one stock in operating margin category among its peers. It also is number one stock in price to book category among its peers fabricating about  11.76  of Price To Book per Operating Margin. Comparative valuation analysis is a catch-all model that can be used if you cannot value Jinhe Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Jinhe Biotechnology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Jinhe Price To Book vs. Operating Margin

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Jinhe Biotechnology

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
0.13 %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Jinhe Biotechnology

P/B

 = 

MV Per Share

BV Per Share

 = 
1.54 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Jinhe Price To Book Comparison

Jinhe Biotechnology is currently under evaluation in price to book category among its peers.

Jinhe Biotechnology Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Jinhe Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Jinhe Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Jinhe Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Jinhe Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income170 M155.2 M
Operating Income187.7 M167.7 M
Income Before Tax101.5 M139.9 M
Net Income Applicable To Common Shares86.9 M112.1 M
Net Income86.5 M111 M
Income Tax Expense924.9 K878.7 K
Net Income From Continuing Ops94.4 M109.2 M
Total Other Income Expense Net51 M53.5 M
Net Interest Income13.9 M14.6 M
Interest Income8.4 M8.8 M
Change To Netincome76.2 M79.2 M

Jinhe Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Jinhe Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Jinhe Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Jinhe Biotechnology's important profitability drivers and their relationship over time.

Use Jinhe Biotechnology in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jinhe Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jinhe Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Jinhe Biotechnology Pair Trading

Jinhe Biotechnology Co Pair Trading Analysis

The ability to find closely correlated positions to Jinhe Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jinhe Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jinhe Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jinhe Biotechnology Co to buy it.
The correlation of Jinhe Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jinhe Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jinhe Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Jinhe Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Jinhe Biotechnology position

In addition to having Jinhe Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Real Estate Thematic Idea Now

Real Estate
Real Estate Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Real Estate theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Jinhe Stock

To fully project Jinhe Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Jinhe Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Jinhe Biotechnology's income statement, its balance sheet, and the statement of cash flows.
Potential Jinhe Biotechnology investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Jinhe Biotechnology investors may work on each financial statement separately, they are all related. The changes in Jinhe Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Jinhe Biotechnology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.